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Abstract

Changes in the Expression of Thin Filament-Associated Proteins in Colonic
Smooth Muscle from Mice during Inflammation

By
Reem Alkahtani

A thesis submitted in partial fulfillment of the requirements for the degree of
Masters of Science at Virginia Commonwealth University.

Virginia Commonwealth University, 2011

Director: S. Murthy Karnam, Ph.D.
Professor, Department of Physiology and Biophysics

The contractility of smooth muscle in inflammatory bowel disease and experimental colitis is
reduced due to inhibition of neurotransmitter release and a decrease in the response of smooth
muscle to contractile agonists. We and others have shown that inflammation induced by TNBS
treatment alters the expression and/or activity of signaling molecules involved in the regulation
of Ca2+ mobilization, MLC20 phosphorylation and contraction in colonic smooth muscle.
Although, thin filament- associated proteins such as calponin, caldesmon, tropomyosin and
smoothelin do not directly participate in contraction, they regulate acto-myosin interaction and
thus, muscle contraction. Calponin, caldesmon and tropomyosin inhibit actomyosin interaction
ix

and the inhibition is relieved upon phosphorylation of these proteins. Recent studies have shown
that visceral smooth muscle from smoothelin knockout mice exhibited decreased contraction.
However, the effect of inflammation on the expression of thin filament- associated proteins is not
known. The aim of the present study is to determine the changes in the expression of calponin,
caldesmon, tropomyosin, and smoothelin in colonic circular smooth muscle from TNBS- and
DSS-induced colitis in mice. The animals were euthanized on day 3 and a segment of inflamed
distal colon was removed. Colonic muscle strips from colitis mice and control mice were
dissected for western blot and real-time RT-PCR analysis; contraction was measured by scanning
micrometry in cells isolated from the muscle strips. Contraction in response to acetylcholine in
muscle cells isolated from colonic muscle strips derived from mice with TNBS colitis was
significantly inhibited compared with the response of cells derived from untreated colon or colon
treated with ethanol. Expression of α-actin, γ-actin calponin, caldesmon, smoothelin-A and
tropomyosin mRNA in muscle strips from TNBS or DSS colitis was significantly increased
compared to control animals. Similarly, expression of α-actin, calponin, caldesmon, smoothelinA and tropomyosin protein as determined by western blot was significantly increased compared
to control animals. We conclude that the expression of α-actin, γ -actin calponin, caldesmon,
smoothelin-A and tropomyosin is upregulated in colonic circular smooth muscle from TNBS or
DSS colitis. Increase in the expression of calponin, caldesmon and tropomyosin, which act to
inhibit acto-myosin interaction, could contribute to decrease in smooth muscle contraction.

x

CHAPTER 1: INTRODUCTION

1. SMOOTH MUSCLE
Smooth muscle has wide distribution in the body. The contractile activity of smooth
muscle is critical for normal physiology of vascular system, respiratory system, gastrointestinal
system and the genitourinary systems. Malfunction of smooth muscle in these systems leads to a
variety of clinical disorders. To mediate the contractile function smooth muscle expresses
selective catalog of genes that define the smooth muscle cells from other cell types. The main
contractile apparatus in the smooth muscle consists of two types of filaments: thin filaments and
thick filaments (28, 29, 38, 67, 69, 90, 91). Thin filaments consist of ~42 kDa protein actin,
which exists in vivo as filamentous actin (F-actin), and associated proteins such as caldesmon,
calponin, tropomyosin and smoothelin. Smooth muscle contains similar amounts of actin as
skeletal muscle. Thick filaments are aggregates of myosin molecule, the molecular motor of all
muscles. Each myosin molecule is a hexamer consisting of a pair of myosin heavy chain
(MHC), a pair of 17-kDa essential light chains, and a pair of 20-kDa myosin light chains
(MLC20). Each MHC is asymmetric and contains a globular head at the N-terminus and a
coiled-tail at the C-terminus. The globular head contains ATP binding site, actin binding site
and intrinsic ATPase activity (28, 67).

The interaction of actin with myosin and subsequent

hydrolysis of ATP is the fundamental reaction whereby chemical energy is converted into
mechanical energy. This interaction generates force and shortens muscle as a result of the
1

sliding of overlapping, interdigitating thin and thick filaments. Smooth muscle contains less
myosin than skeletal muscle, but generates as much force as striated muscle. Alternative splicing
of smooth muscle MHC produces 2 C-terminal isoforms (SM1 and SM2) and 2 N-terminal
isoforms (SM-A and SM-B). The SM1 isoform has been demonstrated to form better contractile
filaments compared to SM2 isoform, whereas the SM-B isoform is associated with increased
myosin ATPase activity and increased shortening velocity, a characteristic of phasic phenotype
of smooth muscle, compared with the SM-A isoforms (28, 67).
“Excitation-contraction coupling” in all muscle is initiated by increase in intracellular Ca2+
leading to changes in the activity of, or interactions of, actin and myosin.

However, the

contraction of smooth muscle is far more than a simple calcium switch and involves complex,
and often redundant, signaling pathways that lead to actomyosin interaction. The fine-tuning of
smooth muscle function is made possible mainly because of the dependent acto-myosin
interaction on 20-kDa myosin light chain (MLC20) phosphorylation at Ser19, which is both
necessary and sufficient for acto-myosin interaction (28, 29, 38, 67, 69, 81, 89-91).
Phosphoryaltion and dephophorylation of MLC20 are directly correlated to smooth muscle
contraction and relaxation, respectively, and the levels of MLC20 phosphorylation are regulated
by MLC kinase (MLCK) and MLC phosphatase (MLCP) activity. The complex mechanisms
that regulate MLC20 phosphorylation and acto-myosin interaction include: 1) mechanisms that
regulate acto-myosin interaction through changes in MLC20 phosphorylation levels; 2)
mechanisms that regulate directly acto-myosin interaction via a set of proteins associated with
actin; and 3) mechanisms that regulate cytoskeleton remodeling and transmission and
maintenance of force developed by acto-myosin interaction (67).

2

1.1. Mechanisms involved in the regulation of MLC20 phosphorylation.
1.1.1. MLCK: An essential step in smooth muscle contraction is phosphorylation of the
MLC20 at Ser19, which increases significantly the actin-activated myosin ATPase activity (67,
69, 90, 91). To date, the best-characterized and physiologically important pathway in MLC20
phosphorylation is Ca2+/calmodulin(CaM)-dependent activation of MLCK in response to
increase in intracellular Ca2+ by contractile agonists (38). In vitro studies suggest that MLC20
phosphorylation at Ser19 is also regulated by Ca2+-independent kinases such as integrin-linked
kinase (ILK), zipper interacting protein kinase (ZIPK) and Rho kinase (69, 90, 91).

The

physiological significance of these kinases in terms of MLC20 phosphorylation, however,
remains unclear. MLCK is strictly dependent on Ca2+/CaM for its activation. Stimulation of
smooth muscle by contractile agonists elevates the intracellular concentration of Ca2+ ([Ca2+]i)
via activation of voltage-gated Ca2+ channels, and/or IP3 receptors/Ca2+ channels and causes
Ca2+ to bind to calmodulin (CaM). The affinity of MLCK for CaM is strongest among the CaMdependent protein kinases (38, 98). There are three isoforms of MLCK: ubiquitous smooth
muscle MLCK (smMLCK), restricted cardiac muscle MLCK (cMLCK) and skeletal muscle
MLCK (skMLCK). MLCK of smooth muscle consists of an N-terminal actin-binding domain, Cterminal myosin-binding domain and a central catalytic domain that phosphorylates MLC20. The
region between the catalytic domain and C-terminal domain has been characterized as the
regulatory domain for kinase activity. Due to the interaction of MLCK with actin and myosin, it
is proposed that a mechanism, referred as non-kinase activity of MLCK regulated acto-myosin
interaction, however, the physiological significance of non-kinase activity of MLCK is unknown.
3

Targeted deletion of MLCK in smooth muscle leads to decreased gut motility, urinary bladder
function, and blood pressure, and also significant reduction in MLC20 phosphorylation in
response to contractile agonist. Changes in the expression and/or activity of Ca2+ mobilization
and MLCK regulation pathways lead altered muscle contraction.

1.1.2. MLCP: The [Ca2+]i transient responsible for the activation of MLCK is rapidly and
efficiently dissipated by Ca2+ extrusion from the cell and uptake into sarcoplasmic Ca2+ stores.
This leads to rapid decline in MLCK activity. MLCK activity is also regulated by several
kinases such as Ca2+/calmodulin-dependent protein kinase II, p21-activated protein kinase 1
(PAK1) or AMP-dependent kinase (38, 69).

Phosphorylation of MLCK by these kinases

decreases the affinity for Ca2+/CaM and inhibits the activity. However, agonist-induced MLC20
phosphorylation and contraction are maintained in the absence of elevated [Ca2+]i and MLCK,
and mechanisms responsible for this are largely correlated to inhibition of MLCP.

After

phosphorylation of MLC20 by MLCK, MLC20 is dephosphorylated by MLCP, the activity of
which is regulated by Ca2+-independent mechanisms often referred as Ca2+-sensitization. The
sustained contraction does not reflect Ca2+ sensitization to low levels of Ca2+, because complete
inhibition of MLCP in the absence of Ca2+ induces smooth muscle contraction. This contraction
induced by MLCP inhibitors in the absence of Ca2+ is blocked by high concentrations of nonspecific kinase inhibitors such as staurosporine, implying participation of Ca2+-independent
MLCK kinases, probably ZIP kinase. Intracellular pathways linking receptor activation and
Ca2+-independent contraction have been investigated in several laboratories and identification of
pathways was greatly facilitated by the use of highly selective, cell permeable Rho kinase
inhibitor, Y27632 (69).

The pathways in Ca2+-independent contraction involve G protein
4

activation, MLC20 phosphorylation by a Ca2+-independent protein kinase and inhibition of MLC
phosphatase via Rho kinase and/or protein kinase C (PKC). MLCP holoenzyme is hetertrimer
consisting of a 37-KDa catalytic subunit of type 1 phosphatase (ppicδ), a 110- to 130-KDa
regulatory subunit, known as myosin phosphatase target subunit I or MYPT1, and a 20-kDa
subunit of unknown function (29). Selectivity of PP1 catalytic subunit for myosin is conferred
by the targeting subunit and this subunit potentiates dephosphorylation of MLC by the catalytic
subunit. MYPT1 is abundantly expressed in smooth muscle and alternative splicing of two
exons gives rise to four major MYPT1 isoforms that differs in the presence of a central insert
and/or a leucine zipper motif at the C-terminal end of the protein (LZ+ and LZ− isoforms).
Phosphorylation of MYPT1 in its C-terminus half at Thr696 or Thr853 by Rho kinase or ZIP kinase
fosters dissociation and inhibits activity of the catalytic subunit and, thus MLC20
dephosphorylation (68, 90, 91). MLCP catalytic activity is also dependent on an endogenous
phosphorylation-dependent inhibitor, CPI-17 (PKC-potentiated PP1 inhibitory protein of 17
kDa), which is preferentially expressed in smooth muscle. Phosphorylation of CPI-17 at Thr38
by PKC, and probably by other kinases such as Rho kinase, ZIPK or ILK, greatly augments the
inhibitory effect (69, 89- 91, 98). CPI-17 is phosphorylated in response to contractile agonists
and the phosphorylation is correlated with Ca2+-independent contraction. Thus, MLCP activity
is tightly regulated by Rho kinase/MYPT1 and PKC/CPI-17 pathways and these pathways have
significant impact on MLC20 phosphorylation and muscle contraction.

Changes in the

expression and/or activity of Rho kinase/MYPT1 and PKC/CPI-17 pathways lead altered muscle
contraction.

5

1.2. Mechanisms involved in the regulation of acto-myosin interaction by thin-filament
associated proteins
Contraction is initiated by MLC20 phosphorylation, however, it can be modulated by
other mechanisms, one of which involves the thin-filament associated proteins (15, 28, 59, 67).
In smooth muscle, the predominant thin-filament protein actin exists as polymerized elongated
filament (F-actin) and accounts for 30-50% of total non-collagenous protein. Associated with
actin are tropomyosin, caldesmon, calponin and smoothelin.
1.2.1. Tropomyosin. Tropomyosin is a coiled-coil -helix and cooperates the contractile
filament interaction by virtue of its spanning seven-actin monomers. It has been shown that
binding of myosin to actin leads to movement of tropomyosin and this process is facilitated by
phosphorylation of myosin suggesting a possible participation of tropomyosin in acto-myosin
interaction (28, 67). Tropomyosin also facilitates inhibition of acto-myosin ATPase activity by
caldesmon.

1.2.2. Caldesmon. Caldesmon is a highly conserved protein that binds actin, myosin,
tropomyosin and calmodulin and exists as smooth muscle-specific h-caldesmon and non-muscle
l-caldesmon.

Caldesmon binds to myosin via N-terminal domain and tethers to actin in

conjunction with C-terminal actin binding domain.

Binding of caldesmon to actin causes

inhibition of acto-myosin ATPase activity and suggested to play a role in suppressing contractile
tone. Phosphorylation of caldesmon by ERK1/2 or PKC and binding of Ca2+/CaM to the Cterminal domain of caldesmon in response to contractile agonist appear to reverse the inhibitory
actions of caldesmon (6, 27, 67).

6

1.2.3. Calponin. Calponin is an actin-binding protein and exists as smooth musclespecific basic h1-calponin, cardiac muscle predominant neutral h2-calponin, and acidic calponin
that is not tissue-specific (12, 28, 67). The role of calponin in the regulation of smooth muscle
contraction appears to be distinct and tissue-specific. In the urinary bladder and vas deferens of
calponin knockout mice, a faster shortening velocity was noticed consistent with the hypothesis
that calponin is an inhibitor of acto-myosin ATPase activity. In contrast, in tonic vascular
smooth muscle suppression of calponin caused a decrease in agonist-induced contraction,
suggesting a stimulatory effect of calponin on smooth muscle contraction. Calponin was also
shown to acts as scaffold tethering ERK1/2 and PKC pathways to regulate smooth muscle
contraction.

1.2.4. Smoothelin. Smoothelin is abundantly expressed actin-binding protein and exists
as visceral smooth muscle-specific smoothelin-A and vascular smooth muscle-specific
smoothelin-B (72, 84).

Although smoothelin has been used as a marker for contractile

phenotype of smooth muscle, knowledge on its role in the regulation of smooth muscle
contraction is limited. A role for smoothelin was suggested recently using smoothelin knockout
mice, which demonstrated decreased contraction in response to contractile agonists, however, the
exact mechanism by which smoothelin regulates muscle contraction is not known.

Thus, the importance of thin-filament associated proteins in the regulation of contraction appears
to vary and tissue-specific. Changes in the expression thin-filament associated proteins may
lead to altered muscle contraction (99).

7

1.3. Mechanisms involved in the regulation of cytoskeletal remodeling
In smooth muscle, the non-muscle isoform of actin (e.g., β-actin and γ-cytoplasmic actin)
are associated with cytoskeleton. Studies demonstrating the remodeling of cytoskeleton in
response to contractile agonist raise the possibility that actin cytoskeleton is dynamic and the
cytoskelton remodeling may regulate smooth muscle contraction (67). However, much remains
to be determined regarding the organization of the contractile filaments with respect to the
overall cytoskeleton and the mechanism by which the cytoskeleton remodeling regulates actomyosin interaction. Several hypotheses have proposed which include increase in the strength of
connections between membrane adhesion junctions and actin filaments and facilitating the
transmission of force.

2. INFLAMMATION

Inflammatory bowel diseases are multifactorial in nature and thought to occur as a result
of complex interactions between the immune system and environmental factors. Ulcerative
colitis and Crohn’s disease are the two main inflammatory bowel diseases (IBD) that are
associated with intestinal inflammation. Patients with IBD have altered bowel habits due to
changes in mucosal secretory and absorptive functions as well as colonic motility. Although the
causes of IBD are not fully understood, studies in patients and using animal models suggest that
there is an initial immunological insult that is followed by a dysregulated immune response.
Intestinal homeostasis is coordinated by the responses of different cell types, including both
immune and non-immune cells such as epithelial cells, enteric neurons, interstial cells of Cajal
(ICC) and smooth muscle cells.

The interaction between immune and nonimmune cells is

amplified during inflammation due to release of many proinflammatory cytokines (e.g.,
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interleukin (IL)-1β and tumor necrosis factor (TNF-α) both by immune cell and non-immune
cell, and contribute to the amplification of tissue injury.

2.1. Animal models
A number of animal models of gastrointestinal inflammation have been developed to
characterize the mechanisms underlying pathogenesis of inflammatory bowel diseases. Although
often suspected for not mimicking all the features of IBD due to its multifactorial nature, it is
generally considered that many mouse models of intestinal inflammation resemble aspects of
IBD in humans and provided important insights into the mechanisms that control intestinal
homeostasis and regulate intestinal inflammation, albeit with some limitations (7, 40, 46, 50, 57,
61-63). To date, there are more than 50 mouse models of intestinal inflammation.

The most

widely used animals models are parasitic infection with Trichinella spiralis, and the hapten
2,4,6-trinitrobenzene sulphonic acid (TNBS) and dextran sodium sulphate (DSS) models of
colitis (50, 57, 61-63, 92, 100-103). Intracolonic instillation of a solution of TNBS in ethanol
causes transmural inflammation due to a delayed type hypersensitivity reaction which involves a
T-helper (Th)1 immune response, whereas the immune response to nematode infection involves
Th2 cytokine production. Acute DSS colitis has a Th1 type cytokine profile, but more chronic
model involves features of both Th1 and Th2 immune responses.
2.2. Colonic dysmotility
Both in vivo and in vitro studies in patients and animal models of colitis support the idea
that colitis is accompanied by a decrease in the contractility of smooth muscle from the inflamed
area (16, 27, 40-49, 79, 90). Measurements of in vivo motility patterns in dogs during acetic
acid-induced ileitis, and in rats with acute DSS-induced colitis demonstrated that inflammation
9

decreased the frequency of migrating motor complexes and tone. Since the giant migrating
contractions are responsible for movements of the faecal pellets, it was suggested that
inflammation reduces propulsive motility (62, 71, 78). Similar decrease in pellet propels in vitro
in distal colon was observed in TNBS-induced colitis. A decrease in the spontaneous contractile
activity, and receptor- and non-receptor-mediated contractions were also observed during
inflammation (27).

The changes in motility are regardless of the model used to induce

inflammation that is administration of different chemical compounds such as TNBS, DSS and
acetic acid. Many studies were performed in animal models of gastrointestinal inflammation in
order to elucidate the mechanisms underlying gut dysmotility during inflammatory processes.
These studies have generated a number of concepts that provide insight into how the immune
and motor systems of the gut interface and also clearly demonstrated how the inflammation of
the mucosa causes colonic dysmotility. The mechanisms underlying the colonic dysmotility are
complex and involve multiple mechanisms such as changes in enteric neurotransmission (17-22,
25, 63, 82), afferent sensory input (5, 8, 65), interstitial cells of Cajal (87), and abnormalities of
the effector itself, the enteric smooth muscle intrinsic smooth muscle contractility (1-4, 31, 32,
35-37, 57, 93-96).

In addition, studies in animal models of inflammation have suggested that

changes in enterochromaffin cell number and 5-HT release and reuptake result in colonic
dysmotility (49, 50, 55).
2.2.1. Enteric Nervous system. The neurons and the glia of the myenteric plexus, which
is located between the longitudinal and circular smooth muscle layers of the muscularis externa,
and the submucosal plexus, which is located in the submucosa constitute the enteric nervous
system (9-11, 26). Because of the importance of ENS in gut functions, several studies have
focused on changes in ENS and structure and function in patients with IBD or in animal models
10

of gut inflammation (7-9, 24, 30, 47-56, 64, 73). The nature of the changes in the ENS in IBD
appear to be dependent on the disease (Crohn's vs. ulcerative colitis), the region of the intestinal
wall and whether or not the tissue was from a site of active inflammation. Both the structure and
function of the enteric nervous system (ENS) are substantially altered in enteric inflammation.
These include a significant decrease in the number of myenteric and submucosal neurons during
colitis, ganglion cell and axonal degeneration and necrosis, and impaired release of
neurotransmitters acetylcholine, noradrenaline, and nitric oxide. Because of their projections to
the mucosal layer, where inflammation is centered, AH neurons, which serve as primary afferent
and interneuronal functions, appear to be more susceptible to inflammation (51, 52). Studies in
patients with IBD and in animal models of inflammation revealed that the immunoreactivity of
vanilloid receptor TRPV1, an integrator of noxious/inflammatory stimuli on sensory nerves that
contributes to inflammation-induced sensory dysfunction, is greatly increased in colonic nerve
fibers (10, 24, 60). Many of these changes in the structure and function are implicated in altered
sensory, secretory and motor function of the intestine during inflammation.

Inflammatory

cytokines and infiltrating immune cells are responsible for many of the changes to the ENS in
inflammation. The extent of damage to ENS function depends on the animal model and species,
probably due to differences in the pathogenesis of inflammatory conditions.

Studies also

indicate that neuronal changes are not limited to the region of inflammation, but can occur in
regions proximal or distal to the site of inflammation (71). Thus, plasticity of ENS is a feature of
intestinal inflammation and several potentially relevant mechanisms underlying ENS plasticity
have also been studied including the role of neurotrophins and enteric glia.
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2.2.2. Interstitial cells of Cajal (ICC). ICC are mesenchymal cells with small cell
bodies and several elongated processes and express c-kit, the proto-oncogene that encodes the
receptor tyrosine kinase, kit. ICC present between longitudinal and circular muscle layers (ICCMY) are spontaneously active and generate slow wave depolarization in different parts of the GI
tract, and are important as pacemakers. Changes in the number of ICC and ultrastructure were
reported in animal models of colitis and in patients with Crohn’s disease and ulcerative colitis
(87).

The reduction in ICC number was associated with an inhibition of spontaneous

contractions of colon. However, more studies of colonic pacemaker activity in IBD are needed
for further insight on the role of ICC in colonic dysmotility.

2.2.3. Smooth muscle. The smooth muscle cells of the gastrointestinal tract are the final
effectors of force development and work. Smooth muscle cells are capable of synthesizing and
secreting a variety of pro- and anti-inflammatory mediators, including cytokines, chemokines,
growth factors, and cell-adhesion molecules that contribute to the maintenance and resolution of
the inflammatory response in the gut (88, 96, 97). Thus, smooth muscle cells act as both source
and target of these mediators. Substantial changes to smooth muscle structure and function have
also been shown in intestinal inflammation. Studies have shown that inflammatory mediators
either decrease or increase smooth muscle contractility and the response appears to be tissue- and
cytokine-specific (1-4, 85, 92-96). Inflammation induced by helminth infection resulted in
hypercontractility of longitudinal muscle via IL-4 and IL-13, whereas inflammation induced by
TNBS or DSS resulted in hypocontractility of circular muscle via IL-1β, TNF-α or ICAM-1.
Several targets in the signaling pathways mediating contraction that are affected by inflammatory
cytokines have been identified and the changes in the expression or activity of these targets are
12

linked to altered muscle contraction. The myogenic mechanisms for decreased contraction
include changes signaling pathways that lead to altered Ca2+ mobilization and MCL20
phosphorylation (1-4, 13, 14, 31, 32, 34-37, 74-77, 93-96).
Changes in Ca2+ mobilization.

Changes in Ca2+ mobilization is implicated in the

dysmotility of colon from ulcerative colitis patients and in animal models of colitis (1-4, 35-37,
39, 93-96). Studies in both TNBS- and DSS-colitis have provided evidence for the decrease in
voltage-dependent Ca2+ currents, and the decrease in Ca2+ currents has been attributed to either
decrease in protein expression or altered regulation of the channel. Decrease in expression was
due to activation of transcription factor, NF-kB and altered regulation was due to inhibition of
tyrosine phosphorylation by Src kinase (35-37, 85-86, 93, 96,). In addition to the effect on Ca2+
channels, inflammation enhances the ATP-sensitive K+ channels expression and currents (34).
Decrease in Ca2+ currents and increase in K+ currents may act cooperatively to decrease smooth
muscle contraction. In addition to Ca2+ and K+ channel functions, SERCA2 expression was
reported to be decreased in colonic muscle during colitis, suggesting that reduced SR Ca2+
uptake can also disrupt intracellular Ca2+ mobilization in smooth muscles from inflamed colon
(4). Studies on human colonic and esophageal sphincter smooth muscle suggest a role for
endogenous H2O2 in the regulation of Ca2+ mobilization and SERCA2 activity in acute
inflammation or upon exposure to IL-1 (13-14). Studies also demonstrated that m3 receptor
binding and Gq protein expression were not altered by exposure to IL-1, whereas PLC-
activity was inhibited. The inhibitory effect of IL-1β on PLC-β1 activity was attributed to upregulation of RGS4 (regulator of G protein signaling), since Gαq-GTP activity is rapidly
terminated by RGS4. Inhibition of PLC-β1 activity leads to decrease in IP3 generation and IP313

dependent Ca2+ release. Analysis of signaling pathways necessary for upregulation of RGS4
suggests that colonic smooth muscle employ multiple signaling pathways such as PI3kinase/Akt, MAP kinases, and NF-kB, which is an immediate early nuclear transcription factor
that is activated in response to proinflammatory cytokines (31-33).

Changes in MLC20 phosphorylation. Previous studies also demonstrated that colonic
inflammation impairs signal transduction pathways related to MLC20 phosphorylation. Levels
of MLC20 phosphorylation are regulated by the balance between MLCK activity and MLCP
activity. Phosphorylation of CPI-17, an endogenous inhibitor of MLCP, by PKC and MYPT1, a
targeting subunit of MLCP, by Rho kinase in response to acetylcholine is essential for inhibition
of MLC phosphatase and maintenance of sustained MLC20 phosphorylation and contraction.
Both IL-1β and TNF-α down regulates expression of CPI-17, which leads to inhibition of
MLC20 phosphorylation and contraction (31, 32, 74-77). CPI-17 expression was also reduced in
smooth muscle from patients with ulcerative colitis. These studies suggest that CPI-17 down
regulation might contribute to the decreased muscle contraction in inflammatory bowel diseases.
The mechanisms involved in the down-regulation of CPI-17 remain unknown.

As discussed in previous section, acto-myosin interaction and thus, muscle contraction are
modulated the thin-filament associated proteins. The involvement of molecular components of
contractile apparatus, particularly thin-filament associated proteins in colonic inflammation has
not been addressed. Changes in the expression of caldesmon, calponin or tropomyosin that
regulate the acto-myosin interaction could probably underlie the altered smooth muscle
contraction.
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It is our hypothesis that the expression of thin filament-associated proteins is altered
during inflammation and contributes to the decreased contraction of colonic smooth muscle.

The aim of the present study was to determine the changes in the expression of actin
isoforms and actin-associated proteins such as caldesmon, calponin, tropomyosin, and
smoothelin-A in colonic smooth muscle isolated from mouse colon following TNBS- and DSSinduced colitis.
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CHAPTER 2: MATERIALS AND METHODS

1. Materials
1.1 Chemicals and antibodies. Collagenase CLS type II and soybean trypsin inhibitor were
obtained from Worthington, Freehold, NJ; Western blotting, and protein assay kit, Tris-HCl
Ready Gels were obtained from Bio-Rad Laboratories, Hercules, CA; antibodies to α-actin, hcaldesmon, h1-calponin, -tropomyosin, smoothelin-A were obtained from Santa Cruz
biotechnology, Santa Cruz, CA; RNAqueousTM kit was obtained from Ambion, Austin, TX;
Effectene Transfection Reagent, QIAEX®II Gel extraction Kit and QIAprep®Spin Miniprep Kit
were obtained from QIAGEN Sciences, Maryland; PCR reagents were obtained from Applied
Biosystems, Roche. 2, 4, 6 trinitrobenzene sulphonic acid (TNBS) and all other chemicals were
obtained from Sigma, St. Louis, MO.
1.2 Animals.

C57BL/6J mice were obtained from Charles River and housed in pairs in

microfilter-isolated cages for 7 days before use with access to food and water. Animal care and
treatment were conducted in accordance with the Institutional guidelines of the Virginia
Commonwealth University.

Institutional Animal Care and Use Committee at the Virginia

Commonwealth University approved all the experimental protocols.
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2. Methods

2.1 Induction of colitis. For TNBS-induced colitis, 6- to 8-weeks old male adult mice were
fasted for 24 h before the induction of inflammation. Colonic inflammation was induced by
intraluminal administration of single dose of TNBS (2.5% in 50% ethanol (v/v)). Mice were
briefly anesthetized with isoflurane and 100 µl of TNBS solution was injected via a catheter
advanced to 3 cm proximal to the anus via 1 ml syringe fitted with a catheter, and the mouse was
kept in a vertical position with the head downwards for 1 min after the administration of the
hapten, in order to distribute the agents within the entire colon. Age-matched mice treated with
vehicle only served as controls (57, 85, 86). Each group of mice was euthanized 3 days after the
induction of inflammation.

For DSS-induced colitis, 6- to 8-weeks old male adults were

administered 5% w/v DSS (MW = 36 000–50 000 Da, MP Biomedicals LLC, Solon, OH, USA)
ad libitum in the drinking water for 5 days (35). All Mice were checked daily for loss of body
weight, stool consistency and the presence of gross bleeding. Colonic tissue from mice treated
with TNBS or DSS exhibited typical histological characteristics of colitis (35, 57, 85, 86).

2.2 Collection of tissue. Mice were euthanized by CO2 inhalation followed by decapitation.
Two- to three centimeter-long segments of the distal colon (starting from ~0.5 cm oral to the
pelvic flexure) were obtained, immediately examined with the naked eye for macroscopic
lesions, opened along the mesenteric border, cleaned, and pinned flat in a Petri dish with Sylgard
base. The mucosal/submucosal layers were separated by microdissection. The muscularis
propria, which included both the circular and longitudinal muscle layers were then quick frozen
in liquid nitrogen and broken into small particles with a chilled pestle for protein and RNA
extractions. The tissue particles were homogenized on ice in phosphate-buffered saline
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supplemented with protease inhibitors for protein extraction. For isolation of dispersed muscle
cell, colon was emptied of its contents and placed in a cold smooth muscle buffer with the
following composition: NaCl 120 mM, KCl 4 mM, KH2PO4 2.6 mM, CaCl2 2.0 mM, MgCl2 0.6
mM, HEPES (N-2-hydroxyethylpiperazine-N’ 2-ethanesulfonic acid) 25 mM, glucose 14 mM,
and essential amino mixture 2.1% (pH 7.4) (31, 32, 57).
2.3 Preparation of dispersed colonic smooth muscle cells. Smooth muscle cells from colonic
smooth muscle were isolated by sequential enzymatic digestion of muscle strips, filtration, and
centrifugation as described previously (31, 32, 57, 70). Colonic muscle were incubated for 20
min in a smooth muscle buffer at 31C containing 0.1% collagenase (300 U/ml) and 0.01%
soybean trypsin inhibitor (w/v). The tissue was continuously gassed with 100% oxygen during
the entire isolation procedure. The partly digested tissues were washed twice with 50-ml of
collagenase-free smooth muscle buffer and the muscle cells were allowed to disperse
spontaneously for 30 min in collagenase-free medium. Cells were harvested by filtration through
500 μm Nitex and centrifuged twice at 350 g for 10 min to eliminate broken cells and organelles.
The cells were counted in a hemocytometer and it is estimated that 95% of the cells excluded
trypan blue. The experiments were done within 2-3 h of cell dispersion.

2.4

Quantitative real-time RT-PCR analysis (qRT-PCR). Total RNA was isolated from

colonic muscle strips with TRIzol® reagent (Invitrogen) and then treated with TURBO DNase
(Ambion). RNA from each preparation was reversely transcribed using the SuperScript™ II
system containing 50 mM Tris–HCl (pH 8.3), 75 mM KCl, 3 mM MgCl2, 10 mM dithiothreitol
(DTT), 0.5 mM deoxynucleoside triphosphates (dNTP), 2.5 μM random hexamers and 200 units
of reverse transcriptase in a 20 μl reaction volume. The reactions were carried out at room
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temperature for 10 min and at 42°C for 50 min, and terminated by heating at 70°C for 15 min
(31, 32, 57). Quantitative RT-PCR was performed on cDNA samples using specific primers
designed based on known sequences in mouse and TaqMan gene expression master mix. The
procedure is based on the time point during PCR cycling when amplification of PCR product is
first detected rather than by the amount of PCR product accumulated after a fixed number of
cycles. The target gene copy number is quantified by measuring threshold cycle parameter (Ct),
defined as fractional cycle at which the fluorescence generated by cleavage of probe passes a
fixed threshold above the base line, and by using a standard curve to determine the starting copy
-ΔΔCT

number. The primers are designed to satisfy the requirements for use of the 2

quantification

method. GAPDH expression was chosen to normalize the expression of the target genes. The
GAPDH amplicon was utilized to normalize and calculate the quantitative expression of various
genes. Thus, a quantitative comparison between samples from control and TNBS- or DSS-treated
-ΔΔCT

animal was calculated with the 2

method by normalizing the ΔCT counts to GAPDH

expression. Expression of the target gene mRNA was divided by the GAPDH mRNA. Final
results are expressed as fold difference in expression in TNBS- or DSS-treated samples relative
to control samples. All PCR reactions were performed in an ABI StepOne Plus PCR (Applied
Biosystems, Foster City, CA). PCR conditions were optimized on the gradient thermal cycler.
For each cDNA sample, real-time PCR was conducted in a 20 μl reaction volume containing
TaqMan gene Expression Master Mix (Applied Biosystems, Foster City, CA). The following
time and temperature profile was used for the real-time PCR reactions: 95 ˚C for 5 min; 40
cycles of a series consisting of 15 s at 94˚C, 30 s at 52˚C, 30 s at 72˚C; and a final extension of 5
min at 72˚C. The optimal annealing temperatures were determined empirically for each primer
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set. The sequences of specific primers are listed in the results section. The ABI sequencedetection software and Microsoft Excel were used to calculate the quantities of the mRNAs.

2.5

Western blot Analysis. Frozen colonic tissues (100 mg) were pulverized while immersed

in liquid nitrogen using a mortar. The muscle powder was collected into a glass tube and
homogenized in buffer containing 20% glycerol, 50 mM tris-HCl (pH 6.8), 0.5% (volume per
volume) Tween-20 and protease inhibitors (0.5 mM phenylmethanesulfonyl fluoride, 2 μM
pepstatin, 2 μM antipain and 0.1 mg/ml trypsin inhibitor). The homogenate was centrifuged
(38,000 g) for 15 minutes using a Sorvall centrifuge and the supernatant was collected. After
gently mixing the samples in SDS (final concentration, 1%), they were boiled for 4 minutes and
centrifuged at 10,000 rpm for 15 minutes. The supernatant was collected and the protein
concentration was determined using the DC protein assay kit (BioRad Laboratories, Hercules,
California). Equal amounts (40 μg) of total protein from control and TNBS- and DSS-treated
mice colonic muscle strips were loaded on 10% SDS-PAGE gels, using the buffer solution
composed of 25 mM Tris, 192 mM glycine, 0.1% SDS and transferred to nitrocellulose
membranes with Towbin buffer (25 mM tris, 192 mM glycine and 20% (v/v)) methanol.
Membranes were subsequently blocked in blocking buffer (composition: 50 mM Tris·HCl, 150
mM NaCl, 0.1% Tween 20, and 5% dried milk powder) for 90 min at room temperature. Next,
membranes were incubated overnight at 4°C with primary antibodies [-actin (diluted 1:500), γactin (diluted 1:1000), h-caldesmon (diluted 1:1000), h1-calponin (diluted 1:1000), tropomyosin (diluted 1:1000), and smoothelin-A (diluted 1:1000); all dilutions in blocking
buffer]. After three washes with TBS-Tween 20 (0.1% TBST, containing 50 mM Tris·HCl, 150
20

mM NaCl, and 0.1% Tween 20) of 10 min each, membranes were incubated with horseradish
peroxidase-labeled secondary antibodies (dilution 1:1000-3,000 in blocking buffer) at room
temperature for 90 min, followed by an additional three washes with 0.1% TBST. Bands were
subsequently visualized on film using SuperSignal Femto maximum sensitivity substrate kit
(Pierce, USA) and analyzed by densitometry (31, 32, 70). All bands were normalized to β-actin
expression.
2.6

Immunohistochemistry. Colonic tissue sections from control and TNBS-treated animals

were processed for calponin, caldesmon, tropomyosin and smoothelin-A immunoreactivities
using an on-slide immunostaining technique. After macroscopic observation, full thickness
specimens from control and inflamed tissue and by immersion in 4% paraformadehyde, washed
in PBS (3 × 10 min), cryoprotected in PBS-sucrose (30%), and embedded for cryostat sectioning
in optimal cutting temperature compound. Cross sections (8-10μm) were cut and the slides
containing the sections incubated for 1 h at room temperature with blocking solution containing
5% normal donkey serum (Jackson ImmunoResearch, West Grove, PA) in PBST (0.3% Triton X100 in 0.1 M PBS, pH 7.4). The samples were then incubated in primary antibodies diluted in
PBST containing 5% normal donkey serum overnight at 4 °C. The antibodies (Santa Cruz, CA)
were used at 1:500 (caldesmon), 1:200 (calponin), 1:500 (tropomyosin) and 1: 500 (smoothelin)
dilutions.

After rinsing (3 × 10 min with 0.1 M PBS), the tissue sections were incubated with

fluorescence-conjugated species-specific secondary antibody Alexa 594 (1:200, Molecular
Probes, Eugene, OR) for 2 h at room temperature. Following wash, the slides were coverslipped
with Citifluor (Citifluor Ltd., London). Control sections incubated in the absence of primary or
secondary antibody were also processed and evaluated for specificity or background staining
levels. In the absence of primary antibody, no positive immunostaining for caldesmon, calponin,
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tropomyosin and smoothelin was observed. The specificity of primary antibodies was examined
by western blot analysis.
2.7

Measurement of contraction in dispersed smooth muscle cells. Contraction in freshly

dispersed colonic smooth muscle cells was determined by scanning micrometry as previously
described (32, 70).

An aliquot (0.4 ml) of cells containing approximately 104 cells/ml was

treated with 100 μl of medium containing different concentrations of acetylcholine (ACh; 10 pM
to 1 µM) for 30 s and the reaction was terminated with 1% acrolein at a final concentration of
0.1%. Acrolein kills and fixes cells without affecting the cell length. The resting cell length was
determined in control experiments in which muscle cells were incubated with 100 l of 0.1%
bovine serum albumin without the ACh.

The mean lengths of 50 muscle cells treated with

various agonists was measured by scanning micrometry and compared with the mean lengths of
untreated cells. The contractile response was expressed as the percent decrease in mean cell
length from control cell length.

3. STATISTICAL ANALYSIS

The results were expressed as means  SE of n experiments and analyzed for statistical
significance using Student’s t-test for paired and unpaired values. Each experiment was done on
cells obtained from different animals. Five mice of each group were studied; qRT-PCR and
western blot were performed in duplicate. Differences among multiple groups were tested by
using ANOVA and checked for significance using Fisher's protected least significant difference
test. A probability of p < 0.05 was considered significant.
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Table 1. RT-PCR TaqMan primers for the amplification of thin-filaments associated
proteins

23

Table 1

Primer set

Aaaay ID

Company name

Product size

Cnn1

Mm00487032- m1

Applied Biosystems

59 bp

Cald1

Mm00513995- m1

Applied Biosystems

102 bp

Tpm2

Mm00437172- g1

Applied Biosystems

97 bp

Smtn

Mm00449973- m1

Applied Biosystems

66 bp

GAPDH

NM-008084.2

Applied Biosystems

107 bp
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Table 2. RT-PCR SYBRgreen primers for the amplification of thin-filaments associated
proteins
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Table 2

Primer
set

Forward 5'3'

Reverse 3'5'

Product
size

α-actin

CGCTGTCAGGAACCCTGAGA

CGAAGCCGGCCTTACAGA

103 bp

γ-actin

GTCCCTGCCATGTATGTTGCTA

GGTACGGCCGGATGCAT

60 bp

IL-1B

TACCTGTGGCCTTGGGCCTCAA

GCTTGGGATCCACACTCTCCAGCT

99 bp

TTGGTGGTTTGCTACGACGTGGG

81 bp

GGAGTTGCTGTTGAAGTCG

122 bp

TNF-α ATGGCCCAGACCCTCACACTCAG

GAPDH

AGAAACCTGCCAAGTATGATG
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Table 3. Western blot antibodies for thin-filaments associated proteins
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Table 3

Antibody

Catalog#

Product size
(kDa)

Company
name

Dilution

Calponin 1
(CALP)

Sc-58707

33-36

SANTA CRUZ

1/1000

Caldesmon

sc-15374

90-150

SANTA CRUZ

1/1000

sc-28543

35-45

SANTA CRUZ

1/1000

Sc-20481

115

SANTA CRUZ

1/1000

Alpha-actin

Clone E184

43

MILLIPORE

1/1000

Gamma-actin

AB 3265

42

CHEMICON
TEMECULA

1/1000

(H-300)

Tropomyosin
(FL-284)

Smoothelin
(C-20)
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CHAPTER 3: RESULTS

In the present study, we analyzed the changes in the expression of α-actin, γ-actin,
caldesmon, calponin, tropomyosin and smoothelin-A in smooth muscle of colon isolated from
control mice and TNBS- and DSS-induced colitic mice by qRT-PCR and Western blot.
For q-RT-PCR specific primers were designed based on known sequences in mouse
(Table 1and 2). The accuracy of the designed primers was evaluated with gel-electrophoresis.
Melt curve analyses showed single peaks for all samples. The PCR efficiencies were calculated
from standard curves.

These findings validated the design of primers and satisfied the
-ΔΔCT

requirements for use of the 2
and Methods section.

quantification method, described previously in the Materials

GAPDH expression was chosen to normalize the expression of the

contractile proteins. The GAPDH amplicon was utilized to normalize and calculate the
quantitative expression of various genes. Thus, a quantitative comparison between inflamed and
-ΔΔCT

normal tissue was calculated with the 2

method by normalizing the ΔCT counts to GAPDH

expression.
For western blot analysis equal amounts of protein were subjected to electrophoresis and
transferred to nitrocellulose or polyvinylidene difluoride membranes. Membranes were incubated
with antibodies to α-actin, γ-actin, h-caldesmon, calponin, tropomyosin or smoothelin-A with
appropriate dilutions (Table 3). Following ECL protocol as described in the Methods, protein
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bands of the expected size were analyzed by densitometry and all bands normalized to β-actin
expression.
For immunohistochemistry tissue sections were incubated in primary antibodies followed
by fluorescence-conjugated species-specific secondary antibody. Control sections incubated in
the absence of primary or secondary antibody showed no positive staining. The specificity of
antibodies used was confirmed by western blot analysis.

3.1 Evaluation of colonic inflammation

Macroscopic examination of the distal colon rectum 5days after TNBS administration
revealed multiple mucosal erosions and ulceration which were in sharp contrast with the
appearance of the normal colon excised from control animals with intact smooth mucosa. IL-1β,
as a vital proinflammatory cytokine, plays an important role in colitis (86, 93, 97). The release
of this cytokine in turn increases the expression of other cytokines and positively contributes to
the progress of inflammatory bowel disease and experimental colitis in animal models of
inflammatory bowel disease. Previous studies demonstrated that IL-1β or TNF-α acting on
muscle cells alters the expression of signaling proteins involved in the regulation of contraction
(31, 32, 93). Therefore, we tested whether the expression of IL-1β increases in smooth muscle
tissue during TNBS- and DSS-induced colitis. Expression of IL-1β and TNF-α was measured
by

qRT-PCR

using

specific

primers

(IL-1

β:

forward

primer,

TACCTGTGGCCTTGGGCCTCAA; reverse primer, GCTTGGGATCCACACTCTCCAGCT
and

TNF-α

forward

primer,

ATGGCCCAGACCCTCACACTCAG;

reverse

primer,

TTGGTGGTTTGCTACGACGTGGG). Indeed, the expression of both IL-1β and TNF-α was
significantly increased (IL-β: 10-fold and 75-fold with TNBS and DSS, respectively, and TNF-α:
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3-fold and 4-fold with TNBS and DSS, respectively, p<0.05, n=3-5) in inflammatory colonic
tissue in colitis compared to control tissue (Figs. 1 and 2). These results strongly suggested that
TNBS-treatment results in the generation of proinflammatory cytokines.
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Figure 1. Expression of IL-1β in the colonic muscle after TNBS or DSS treatment. Total
RNA isolated from smooth muscle strips of control and TNBS or DSS treated mice using
RNAqueous prep kits (Ambion, Austin, Tx) and was reverse transcribed using 2 µg of total RNA
using qScript cDNA prep kits (Quanta, Gaithersburg, MD). The cDNA was amplified with
specific primers for IL-1β. The sequences of specific primers are listed in Table 1. Quantitative
real-time polymerase chain reaction (qRT-PCR) was used to measure RNA levels of IL-1β. For
each cDNA sample, real-time PCR was conducted in a 20-μl reaction volume containing
TM

Quantitect

SYBRgreen PCR Mastermix (Qiagen, Mississauga, ON). Real-time PCR reactions

were performed in triplicate. Results are expressed as fold differences in IL-1β gene expression
in TNBS- or DSS-treated colon relative to that in vehicle-treated colon. Values represent the
means SEM of 5 separate experiments. **p<0.001 versus control.
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Figure 1
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Figure 2. Expression of TNF-α in the colonic muscle after TNBS or DSS treatment. Total
RNA isolated from smooth muscle strips of control and TNBS or DSS treated mice using
RNAqueous prep kits (Ambion, Austin, Tx) and was reverse transcribed using 2 µg of total RNA
using qScript cDNA prep kits (Quanta, Gaithersburg, MD). The cDNA was amplified with
specific primers for TNF-α. Quantitative real-time polymerase chain reaction (qRT-PCR) was
used to measure RNA levels of TNF-α. For each cDNA sample, real-time PCR was conducted
in a 20-μl reaction volume containing Quantitect

TM

SYBRgreen PCR Mastermix (Qiagen,

Mississauga, ON). Real-time PCR reactions were performed in triplicate. Results are expressed
as fold differences in TNF-α gene expression in TNBS- or DSS-treated colon relative to that in
vehicle-treated colon. Values represent the means SEM of 3 separate experiments. **p<0.05
versus control.
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Figure 2
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3.2

Changes in the expression of thin-filament associated proteins in TNBS-colitis mice.
3.2.1 Actins. Six actin isoforms (α-skeletal, α-cardiac, and α-vascular; γ-enteric and γ-

cytoplasmic; and β-cytoplasmic) have been described and are products of separate genes (28,
67). The α-vascular and γ-enteric actin isoforms are smooth muscle specific and associated with
the contractile proteins, whereas β- and γ-cytoplasmic actins are non-muscle isoforms and
associated with non-contractile cytoskeleton. Expression of - and -actin was measured in
colonic muscle of control and TNBS-colitic mice. The differences in the expression levels were
analyzed

by

qRT-PCR

using

specific

primers

(-actin:

forward

primer,

CGCTGTCAGGAACCCTGAGA; reverse primer, CGAAGCCGGCCTTACAGA and γ-actin:
forward

primer,

GTCCCTGCCATGTATGTTGCTA;

reverse

primer,

GGTACGGCCGGATGCAT). The results showed that expression of α-actin and -actin was 2fold higher (p<0.05, n=5) in colonic muscle cells from TNBS mice compared to control mice
(Figs. 3 and 4). Protein expression of α-actin protein was examined by western blot analysis
using an antibody that recognizes selectively α-actin. Results showed expression of one protein
band with ~45kDa and the molecular weight of the protein band corresponds to the expected
molecular weight of α-actin isoform (42 kDa).

Comparing the densities of protein bands

revealed 3-fold higher expression in muscle from TNBS mice compared to control mice (Fig. 3)
(p<0.05). α-actin immunoreactivity was also observed from colonic tissue sections of both
control and TNBS-treated mice and the immunoreactivity was predominant in muscularis propria
and intensity of immunoreactivity appears to be greater in tissues from TNBS mice compared to
control mice (Fig. 3)
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3.2.2. Caldesmon. Two caldesmon isoforms (h-caldesmon and l-caldesmon) have been
described. The h-caldesmon is smooth muscle specific, whereas l-caldesmon is non-muscle
isofrom (6). Expression of h-caldesmon was measured in colonic muscle of control and TNBScolitic mice. The differences in the expression levels were analyzed by qRT-PCR using specific
primers (assay ID: Mm00513995- m1, Applied Biosystems). The results showed that expression
of h-caldesmon was 7-fold higher (p<0.001) in colonic muscle cells from TNBS mice compared
to control mice (Fig. 5). Protein expression of h-caldesmon was examined by western blot
analysis using an antibody that recognizes selectively h-caldesmon. Results showed expression
of one protein band with ~100 kDa and the molecular weight of the protein band corresponds to
the expected molecular weight of h-caldesmon isoform. Comparing the densities of protein
revealed 2.5-fold higher (p<0.05) expression in muscle from TNBS mice compared to control
mice (Fig. 5). h-caldesmon immunoreactivity was observed from colonic tissue sections of both
control and TNBS-treated mice and the immunoreactivity was predominant in muscularis propria
and intensity of immunoreactivity appears to be greater in tissues from TNBS mice compared to
control mice (Fig. 5).

3.2.3. Calponin.

Three calponin isoforms (h1-acidic, h2-neutral and basic calponin)

have been described. The h2-acidic is smooth muscle specific, whereas h2-neutral and basic
calponin are non-muscle isoforms (12). Expression of h2-calponin was measured in colonic
muscle of control and TNBS-colitic mice.

The differences in the expression levels were

analyzed by qRT-PCR using specific primers (assay ID: Mm00487032-m1, Applied
Biosystems). The results showed that expression of h2-calponin was ~4-fold higher (p<0.001) in
colonic muscle cells from TNBS mice compared to control mice (Fig. 6). Protein expression of
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h-calponin also examined by western blot analysis using an antibody that recognizes selectively
h2-calponin. Results showed expression of one protein band with 35 kDa and the molecular
weight of the protein band corresponds to the expected molecular weight of h2-calponin
isoforms.

Comparing the densities of protein revealed 3-fold higher (p<0.001) expression in

muscle from TNBS mice compared to control mice (Fig. 6). h1-calponin immunoreactivity was
observed from colonic tissue sections of both control and TNBS-treated mice and the
immunoreactivity was predominant in muscularis propria and intensity of immunoreactivity
appears to be greater in tissues from TNBS mice compared to control mice (Fig. 6).

3.2.4. Tropomyosin.
described (28, 67).

Two tropomyosin isoforms (α- and β-tropomyosin) have been

Expression of α-tropomyosin was measured in colonic muscle of control

and TNBS-colitic mice. The differences in the expression levels were analyzed by qRT-PCR
using specific primer (assay ID: Mm00437172-g1, Applied Biosystems). The results showed
that expression of α-tropomyosin was 2-fold higher in colonic muscle cells from TNBS mice
compared to control mice (Fig. 7). Protein expression of α-tropomyosin was examined by
western blot analysis using an antibody that recognizes both isoforms.

Results showed

expression of one protein band with ~35 kDa and the molecular weight of the protein band
corresponds to the expected molecular weight of α-tropomyosin. Comparing the densities of
protein revealed a 2.5-fold higher (p<0.05) expression in muscle from TNBS mice compared to
control mice (Fig. 7). Α tropomyosin immunoreactivity was also observed from colonic tissue
sections of both control and TNBS-treated mice and the immunoreactivity was predominant in
muscularis propria and intensity of immunoreactivity appear to be greater in tissues from TNBS
mice compared to control mice (Fig. 7).
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3.2.5. Smoothelin.
described.

Two smoothelin isoforms (Smoothelin-A and -B) have been

Expression of smoothelin-A is specific to visceral smooth muscle, whereas

smoothelin-B is specific to vascular smooth muscle (72, 84). Smoothelin-A was measured in
colonic muscle of control and TNBS-colitic mice. The differences in the expression levels were
analyzed by qRT-PCR using specific primers (assay ID: Mm00449973-m1, Applied
Biosystems). The results showed that expression of smoothelin-A was 2-fold greater in colonic
muscle cells from TNBS mice compared to control mice (Fig. 8).

Protein expression of

smoothelin-A was also examined by western blot analysis using an antibody that recognizes both
isoforms. Results showed expression of one protein band with 60 kDa and the molecular weight
of the protein band corresponds to the expected molecular weight of smoothelin-A. Comparing
the densities of protein revealed 2-fold higher expression in muscle from TNBS mice compared
to control mice (Fig. 8). Smoothelin-A immunoreactivity was observed from colonic tissue
sections of both control and TNBS-treated mice and the immunoreactivity was predominant in
muscularis propria and intensity of immunoreactivity appears to be greater in tissues from TNBS
mice compared to control mice (Fig. 8)
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Figure 3. Expression of -actin in the colonic muscle after TNBS treatment. (A) mRNA
expression. Total RNA isolated from smooth muscle strips of control and TNBS treated mice
using RNAqueous prep kits (Ambion, Austin, Tx) and was reverse transcribed using 2 µg of total
RNA using qScript cDNA prep kits (Quanta, Gaithersburg, MD). The cDNA was amplified with
specific primers for -actin. Quantitative real-time polymerase chain reaction (qRT-PCR) was
used measure RNA levels of -actin. For each cDNA sample, real-time PCR was conducted in a
20-μl reaction volume containing Quantitect

TM

SYBRgreen PCR Mastermix (Qiagen,

Mississauga, ON). Real-time PCR reactions were performed in triplicate. Results are expressed
as fold differences in -actin gene expression in TNBS-treated colon relative to that in control
colon. Values represent the means SEM of 5 separate experiments. *p<0.05 versus control. (B)
Protein expression. Colonic muscle tissue lysates containing equal amounts of total proteins
were separated with SDS-PAGE and expression of -actin was analyzed using selective
antibody. Results are expressed as fold differences in -actin protein expression in TNBS-treated
colon relative to that in vehicle-treated colon. Values represent the means SEM of 5 separate
experiments.

*p<0.05 versus control.

(C) Immunohistochemistry.

Representative

photomicrographs for -actin staining in control and TNBS-treated colon. Note increase in the
staining for -actin in tissue sections from TNBS-treated animals.
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Figure 3
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Figure 4. Expression of γ-actin in the colonic muscle after TNBS treatment. Total RNA
isolated from smooth muscle strips of control and TNBS treated mice using RNAqueous prep
kits and was reverse transcribed using 2 µg of total RNA. The cDNA was amplified with
specific primers for γ-actin. Quantitative real-time polymerase chain reaction (qRT-PCR) was
used measure RNA levels of γ-actin. For each cDNA sample, real-time PCR was conducted in a
20-μl reaction volume containing Quantitect

TM

SYBRgreen PCR Mastermix. Real-time PCR

reactions were performed in triplicate. Results are expressed as fold differences in γ-actin gene
expression in TNBS-treated colon relative to that in control colon. Values represent the means
SEM of 5 separate experiments.
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Figure: 4
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Figure 5. Expression of h-caldesmon in the colonic muscle after TNBS treatment. (A)
mRNA expression. Total RNA isolated from smooth muscle strips of control and TNBS treated
mice using RNAqueous prep kit and was reverse transcribed using 2 µg of total RNA using
qScript cDNA prep kits. The cDNA was amplified with specific primers for h-caldesmon.
Quantitative real-time polymerase chain reaction (qRT-PCR) was used measure mRNA levels of
h-caldesmon. For each cDNA sample, real-time PCR was conducted in a 20-μl reaction volume
TM

containing Quantitect

TaqMan PCR Mastermix. Real-time PCR reactions were performed in

triplicate. Results are expressed as fold differences in h-caldesmon gene expression in TNBStreated colon relative to that in control colon. Values represent the means SEM of 5 separate
experiments. **p<0.001 versus control. (B) Protein expression. Colonic muscle tissue lysates
containing equal amounts of total proteins were separated with SDS-PAGE and expression of hcaldesmon was analyzed using selective antibody. Results are expressed as fold differences in hcaldesmon protein expression in TNBS-treated colon relative to that in control colon. Values
represent the means SEM of 5 separate experiments.

*p<0.05 versus control.

(C)

Immunohistochemistry. Representative photomicrographs for h-caldesmon staining in control
and TNBS-treated colon. Note increase in the staining for h-caldesmon in tissue sections from
TNBS-treated animals.
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Figure 6. Expression of h1-calponin in the colonic muscle after TNBS treatment. (A)
mRNA expression. Total RNA isolated from smooth muscle strips of control and TNBS treated
mice using RNAqueous prep kit and was reverse transcribed using 2 µg of total RNA using
qScript cDNA prep kits. The cDNA was amplified with specific primers for h1-calponin.
Quantitative real-time polymerase chain reaction (qRT-PCR) was used measure mRNA levels of
h1-calponin. For each cDNA sample, real-time PCR was conducted in a 20-μl reaction volume
TM

containing Quantitect

TaqMan PCR Mastermix. Real-time PCR reactions were performed in

triplicate. Results are expressed as fold differences in h1-calponin gene expression in TNBStreated colon relative to that in control colon. Values represent the means SEM of 5 separate
experiments. **p<0.05 versus control. (B) Protein expression. Colonic muscle tissue lysates
containing equal amounts of total proteins were separated with SDS-PAGE and expression of
h1-calponin was analyzed using selective antibody. Results are expressed as fold differences in
h1-calponin protein expression in TNBS-treated colon relative to that in control colon. Values
represent the means SEM of 5 separate experiments. **p<0.001 versus control. (C)
Immunohistochemistry. Representative photomicrographs for h1-calponin staining in control
and TNBS-treated colon. Note increase in the staining for h-calponin in tissue sections from
TNBS-treated animals. Scale bar = 200 μm.
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Figure 7. Expression of -tropomyosin in the colonic muscle after TNBS treatment. (A)
mRNA expression. Total RNA isolated from smooth muscle strips of control and TNBS treated
mice using RNAqueous prep kit and was reverse transcribed using 2 µg of total RNA using
qScript cDNA prep kits. The cDNA was amplified with specific primers for -tropomyosin.
Quantitative real-time polymerase chain reaction (qRT-PCR) was used measure mRNA levels of
-tropomyosin. For each cDNA sample, real-time PCR was conducted in a 20-μl reaction
TM

volume containing Quantitect

TaqMan PCR Mastermix. Real-time PCR reactions were

performed in triplicate. Results are expressed as fold differences in -tropomyosin gene
expression in TNBS-treated colon relative to that in control colon. Values represent the means
SEM of 5 separate experiments. *p<0.05 versus control. (B) Protein expression. Colonic
muscle tissue lysates containing equal amounts of total proteins were separated with SDS-PAGE
and expression of -tropomyosin was analyzed using selective antibody. Results are expressed
as fold differences in -tropomyosin protein expression in TNBS-treated colon relative to that in
control colon. Values represent the means SEM of 5 separate experiments. *p<0.05 versus
control. (C) Immunohistochemistry. Representative photomicrographs for -tropomyosin
staining in control and TNBS-treated colon. Note increase in the staining for h-calponin in tissue
sections from TNBS-treated animals.
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Figure 8. Expression of smoothelin-A in the colonic muscle after TNBS treatment. (A)
mRNA expression. Total RNA isolated from smooth muscle strips of control and TNBS treated
mice using RNAqueous prep kit and was reverse transcribed using 2 µg of total RNA using
qScript cDNA prep kits. The cDNA was amplified with specific primers for smoothelin-A.
Quantitative real-time polymerase chain reaction (qRT-PCR) was used measure mRNA levels of
smoothelin-A. For each cDNA sample, real-time PCR was conducted in a 20-μl reaction volume
TM

containing Quantitect

TaqMan PCR Mastermix. Real-time PCR reactions were performed in

triplicate. Results are expressed as fold differences in smoothelin-A gene expression in TNBStreated colon relative to that in control colon. Values represent the means SEM of 5 separate
experiments. (B) Protein expression. Colonic muscle tissue lysates containing equal amounts of
total proteins were separated with SDS-PAGE and expression of smoothelin-A was analyzed
using selective antibody. Results are expressed as fold differences in smoothelin-A protein
expression in TNBS-treated colon relative to that in control colon. Values represent the means
SEM

of

5

separate

experiments.

(C)

Immunohistochemistry.

Representative

photomicrographs for smoothelin-A staining in control and TNBS-treated colon. Note increase
in the staining for h-calponin in tissue sections from TNBS-treated animals.
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3.3. Changes in the expression of thin-filament associated proteins in DSS-colitis mice.
To determine whether the up-regulation of thin filament associated proteins observed in
the colonic muscle of TNBS-induced colitis is also observed in an another model of colitis, mice
were treated with DSS for 5 days and the expression of caldesmon, calponin, tropomyosin and
smoothelin-A were analyzed by qRT-PCR and western blot in colonic smooth muscle isolated
from control and DSS-treated mice. Analysis of mRNA and proteins expression results revealed
higher expression of calponin (~2-fold, Fig. 10), caldesmon (3- to 4-fold; p<0.001, Fig. 9),
tropomyosin (2-3-fold, Fig. 11), and smoothelin-A (~2-fold, Fig. 12) in colonic muscle cells
from DSS mice compared to control mice. These results suggest that inflammation induced by
either TNBS or DSS treatment had similar effect on the expression thin-filament associated
proteins.
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Figure 9. Expression of h-caldesmon in the colonic muscle after DSS treatment. (A) mRNA
expression. Total RNA isolated from smooth muscle strips of control and DSS treated mice
using RNAqueous prep kit and was reverse transcribed using 2 µg of total RNA using qScript
cDNA prep kits. The cDNA was amplified with specific primers for h-caldesmon. Quantitative
real-time polymerase chain reaction (qRT-PCR) was used measure mRNA levels of hcaldesmon. For each cDNA sample, real-time PCR was conducted in a 20-μl reaction volume
TM

containing Quantitect
triplicate.

TaqMan PCR Mastermix. Real-time PCR reactions were performed in

Results are expressed as fold differences in h-caldesmon gene expression in DSS-

treated colon relative to that in control colon. Values represent the means SEM of 5 separate
experiments. **p<0.05 versus control. (B) Protein expression. Colonic muscle tissue lysates
containing equal amounts of total proteins were separated with SDS-PAGE and expression of hcaldesmon was analyzed using selective antibody. Results are expressed as fold differences in hcaldesmon protein expression in DSS-treated colon relative to that in control colon. Values
represent the means SEM of 5 separate experiments. **p<0.05 versus control.
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Figure 10. Expression of h1-calponin in the colonic muscle after DSS treatment. (A)
mRNA expression. Total RNA isolated from smooth muscle strips of control and DSS treated
mice using RNAqueous prep kit and was reverse transcribed using 2 µg of total RNA using
qScript cDNA prep kits. The cDNA was amplified with specific primers for h1-calponin.
Quantitative real-time polymerase chain reaction (qRT-PCR) was used measure mRNA levels of
h1-calponin. For each cDNA sample, real-time PCR was conducted in a 20-μl reaction volume
TM

containing Quantitect
triplicate.

TaqMan PCR Mastermix. Real-time PCR reactions were performed in

Results are expressed as fold differences in h1-calponin gene expression in DSS-

treated colon relative to that in control colon. Values represent the means SEM of 5 separate
experiments. *p<0.05 versus control. (B) Protein expression. Colonic muscle tissue lysates
containing equal amounts of total proteins were separated with SDS-PAGE and expression of
h1-calponin was analyzed using selective antibody. Results are expressed as fold differences in
h1-calponin protein expression in DSS-treated colon relative to that in control colon. Values
represent the means SEM of 5 separate experiments. *p<0.05 versus control.
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Figure 11. Expression of -tropomyosin in the colonic muscle after DSS treatment. (A)
mRNA expression. Total RNA isolated from smooth muscle strips of control and DSS treated
mice using RNAqueous prep kit and was reverse transcribed using 2 µg of total RNA using
qScript cDNA prep kits. The cDNA was amplified with specific primers for -tropomyosin.
Quantitative real-time polymerase chain reaction (qRT-PCR) was used measure mRNA levels of
-tropomyosin. For each cDNA sample, real-time PCR was conducted in a 20-μl reaction
TM

volume containing Quantitect
performed in triplicate.

TaqMan PCR Mastermix.

Real-time PCR reactions were

Results are expressed as fold differences in -tropomyosin gene

expression in DSS-treated colon relative to that in control colon. Values represent the means
SEM of 5 separate experiments. *p<0.05 versus control. (B) Protein expression. Colonic
muscle tissue lysates containing equal amounts of total proteins were separated with SDS-PAGE
and expression of -tropomyosin was analyzed using selective antibody. Results are expressed
as fold differences in -tropomyosin protein expression in DSS-treated colon relative to that in
control colon. Values represent the means SEM of 5 separate experiments. *p<0.05 versus
control.
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Figure 12. Expression of smoothelin-A in the colonic muscle after DSS treatment. (A)
mRNA expression. Total RNA isolated from smooth muscle strips of control and DSS treated
mice using RNAqueous prep kit and was reverse transcribed using 2 µg of total RNA using
qScript cDNA prep kits. The cDNA was amplified with specific primers for smoothelin-A.
Quantitative real-time polymerase chain reaction (qRT-PCR) was used measure mRNA levels of
smoothelin-A. For each cDNA sample, real-time PCR was conducted in a 20-μl reaction volume
TM

containing Quantitect
triplicate.

TaqMan PCR Mastermix. Real-time PCR reactions were performed in

Results are expressed as fold differences in smoothelin-A gene expression in DSS-

treated colon relative to that in control colon. Values represent the means SEM of 5 separate
experiments. (B) Protein expression. Colonic muscle tissue lysates containing equal amounts
of total proteins were separated with SDS-PAGE and expression of smoothelin-A was analyzed
using selective antibody. Results are expressed as fold differences in smoothelin-A protein
expression in DSS-treated colon relative to that in control colon. Values represent the means
SEM of 5 separate experiments. *p<0.05 versus control.
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3.4. Effect of inflammation on muscle contraction.

To determine whether changes in the expression of thin-filament proteins was associated
with changes in agonist-induced contraction, freshly dispersed colonic muscle cells from control
mice and TNBS-colitis mice were treated with different concentrations of acetylcholine and
decrease in muscle cell length was measured by scanning micrometry. Basal muscle cell lengths
were similar in control (954 m) and TNBS-colitis (915 m) and ACh caused contraction that
was concentration-dependent in muscle cells from both control and TNBS-colitis mice (Fig. 13).
However contraction in response to ACh was significantly lower in TNBS-colitis mice compared
to control mice. The maximal response to 0.1 M ACh was also significantly lower in TNBScolitis mice (322% decrease in cell length) compared to control mice (203% decrease in cell
length) (Fig. 13). These results are consistent with the previous studies in several animal models
of inflammation.
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Figure 13. Effect of TNBS treatment on ACh-induced muscle contraction. Contraction of
dispersed muscle cells from colon was measured by scanning micrometry in response to different
concentrations of ACh. Cells were treated with ACh for 30s and contraction was expressed as
percent decrease in cell length from basal cell length: basal length of muscle cells from control
mice 1254 µm; basal control length of muscle cells from TNBS-colitis mice 1185 µm. ACh
caused contraction that was concentration-dependent in both inflamed and control. Contraction
was significantly attenuated in cells from TNBS-colitis mice. The maximal response to 0.1 µM
of ACh was 322% decrease in cell length in control mice and 203% decrease in cell length in
TNBS-colitis mice. Values represent the means SEM of 5 separate experiments. **p<0.05
significant inhibition of contraction compared to control mice.
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CHAPTER 4: DISCUSSION

Altered motility is induced by colonic inflammation, and this abnormality may lead to the
diarrhea or constipation characteristic of IBD. It has been suggested that many factors, including
changes in the function of ENS, ICC and smooth muscle are associated with altered colonic
motility (1-4, 17-22, 25, 35-37, 63, 82, 93-96). The smooth muscle cells of the gastrointestinal
tract are the final effectors of force development and work, and thus, it is important to understand
the changes in expression of contractile proteins, which constitutes the main contractile
apparatus of smooth muscle.

In the present study, we examined the effects of colonic

inflammation on the contractile properties of colonic smooth muscle by two well-characterized
animal models of colitis such as TNBS (hapten)- and DSS-induced mouse models and three
different approaches to measure the changes in the expression such as qRT-PCR, western blot
and immunohistochemistry. Biochemically, the colonic inflammation induced by TNBS or DSS
was characterized by an increased IL-1β expression, which is indicative of inflammation that
occurs in these animal models of colitis, as well as in human IBD (7, 56).
Our main findings are: 1) expression of thin filament proteins involved in acto-myosin
interaction and contraction such as α-actin, γ-actin is increased, 2) expression of thin-filament
associated proteins involved in the regulation of acto-myosin interaction and contraction such as
tropomyosin, smoothelin, calponin and caldesmon is increased, 3) contraction induced by
acetylcholine in isolated smooth muscle cells is decreased by colitis, 4) The changes in the
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expression of contractile proteins is observed at both protein and mRNA levels and the extent of
changes in the expression of contractile proteins is similar in both TNBS- and DSS-induced
colitic models.

The present investigation of the response of the contractile proteins to

inflammation may provide further insights into the mechanism by which inflammation modifies
contractile proteins and suggests that inflammation may contribute to the regulation of the
expression of genes responsible for synthesis of smooth muscle contraction proteins. Chronic
inflammation of the colon also induces both hyperplasia and hypertrophy of the muscle leading
to alterations in the cellular architecture (57). Increase in the expression of contractile proteins,
major components of both contractile apparatus and the cytoskeletal structure of smooth muscle
could contribute to the inflammation-induced changes in smooth muscle cellular architecture.
Although TNBS and DSS are shown to mediate inflammation via distinct inflammatory
mediators, several studies demonstrated similar decrease in spontaneous and agonist-mediated
colonic muscle contraction in both models (16, 27, 40-49, 79, 90). In addition, alterations in
Ca2+ handling and signal transduction pathway involved in muscle contraction are similar in both
models (1-4, 13, 14, 34-37, 74-77, 93-96).

Contraction of smooth muscle is determined by the stimulation of ATPase activity of the myosin
II, the main molecular motor for contraction, upon its interaction with actin. Stimulation of
ATPase activity is greatly facilitated by the phosphorylation of 20-kDa myosin light chains
(MLC20) by MLC kinase (28, 29, 38, 67, 69, 81, 89-91). A high correlation between MLC20
phosphorylation and muscle contraction has been demonstrated previously.

The levels of

MLC20 phosphorylation are regulated by opposing activities of MLC kinase and MLC
phosphatase, whose activities, in turn, are regulated by feedback mechanism such as inhibition of
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MLCK via CaMKII or AMP kinase, and activation or inhibition MLCP via telokin and CPI-17,
respectively (38, 69, 89, 90).

Previous studies have demonstrated that either exposure of

cultured muscle cells in vitro to IL-1β or TNF-α or during inflammation in vivo has specific
effects on the expression and activity of various targets in the signaling pathways mediating
contraction and relaxation (14, 31, 32, 93-96). Colonic inflammation induced by TNBS or DSS
also alters expression and/or activity of Ca2+ channels, K+ channels and SERCA2 suggesting an
imbalance in Ca2+ mobilization mechanisms (1-4, 35-7, 39, 85-86, 94).

Contraction of smooth muscle is determined by mechanisms that regulate the availability of actin
to interact with myosin via the action of inhibitory actin binding proteins such as caldesmon and
calponin (6, 12, 28, 67). These thin-filament associated proteins are capable of stabilizing actin
filaments. Caldesmon is a highly conserved, actin and myosin binding protein and exists in two
isoforms: expression of heavy isoform (h-caldesmon) is specific to smooth muscle cells, whereas
light isoform (l-caldesmon) is expressed in both non-muscle and dedifferentiated smooth muscle
cells. Caldesmon inhibits acto-myosin interaction and the inhibitory is reversed by binding of
Ca2+/CaM or by phosphorylation via ERK1/2 (6, 28, 67). Calponin is an actin binding protein
and exists in three isoforms: expression of h1 calponin (basic calponin) is specific to smooth
muscle, whereas h2 calponin (neutral calponin) and acidic non-muscle. Calponin inhibits actomyosin ATPase activity interaction and the inhibition is reversed by phosphorylation via ERK1/2
or PKC. Thus caldesmon and calponin are important regulators of smooth muscle contraction
(12, 28, 67). Although studies suggest that tropomyosin is necessary for full inhibition of actomyosin activity by caldesmon, the exact mechanism of action is unclear (28, 67).

The data

presented in the current study reveal an association between increases in the expression of thin66

filament associated proteins, especially, caldesmon, calponin and tropomyosin in response to
inflammation and decreased muscle contraction. Caldesmon and calponin inhibit muscle
contraction and actin-activated ATPase activity, and tropomyosin enhances the caldesmoninduced inhibition of actomyosin ATPase. The low force in the presence of high levels of
MLC20 phosphorylation was attributed to the suppression of acto-myosin ATPase activity and
force generation by the high levels of caldesmon and calponin. The cytoskeleton modifications
due to increased expression of thin-filament associated proteins may also have an effect on
smooth muscle contraction.

However, evidence for the cytoskeleton remodeling on cell

contraction is lacking. Thus, our study in combination with previous studies proposes that in
colitis, several mechanisms result in attenuated muscle contraction. First, a lower expression
and/or activity of L-type Ca2+ channels result in decrease in intracellular Ca2+ and inhibition of
Ca2+/CaM-dependent MLCK activity (1-4, 35-37, 96). Second, a lower expression of CPI-17,
an endogenous inhibition of MLCP, results in stimulation of MLCP activity (31, 74-76). Third,
a greater expression of caldesmon and calponin results in attenuation of acto-myosin interaction.
Further investigations might reveal whether the proposed mechanisms are dependent on each
other or occur independently, and whether a singular mechanism is sufficient to produce altered
muscle contraction.

Smoothelin is an actin binding protein and exists in two isoforms:

expression of smoothelin-A is selective to visceral smooth muscle, whereas expression of
smoothelin-B is selective to vascular smooth muscle. Expression of both isoforms is abundant in
contractile smooth muscle cells and limited in non-contractile proliferative smooth muscle cells.
Recent studies using transgenic mice suggest expression of smoothelin-A is important slow wave
activity and agonist-mediated contraction of gastrointestinal smooth muscle (72, 84).

The

increase in the expression of smoothelin-A in colitis suggests that it may be a compensatory
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mechanism to offset the inhibitory effects exerted by increased caldesmon and calponin on
smooth muscle contraction.

The results also suggest that up-regulation of thin-filament associated proteins is due to changes
in the transcriptional regulation of these proteins, probably via the direct effect of
proinflammatory cytokines on the transcription factors. Previous studies demonstrated that
exposure of cultured muscle cells to IL-1β or TNF-α caused change in the transcriptional
regulation of several proteins involved in smooth muscle contraction (31, 32, 93-96). The
decrease in contraction on exposure of smooth muscle to IL-1β or TNF-α was reversed by
inhibitor of nuclear factor-kappa B (NF-B), suggesting that the cytokine effects are mediated
mainly by NF-B. Future studies on the animal models combined with studies on the smooth
muscle cultures exposed to proinflammatory cytokines should provide valuable information on
the direct effects of cytokines on the smooth muscle contractile proteins.

The final common pathway in the regulation of colon motility is the contractility of colonic
muscle. This can be evaluated in vitro using isolated muscle cell preparation. Our studies in
isolated muscle cells demonstrate that contraction induced by acetylcholine is decreased in both
model of colitis. Clearly, changes in muscle contraction observed in vitro should be extrapolated
into the in vivo situation with caution. Consideration must be given to the important roles
mediated by enteric nerves, the ICC, and other endocrine and paracrine factors. In addition, the
roles of circular and longitudinal muscle differ in terms of their contribution to peristaltic activity
and their response to inflammation. However, muscle contraction is an acceptable approach and
important determinant of evaluating how inflammatory and immune cells affect colonic motility.
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In summary, the results of the present study have demonstrated colitis-augmented the
expression of -actin, γ-actin, tropomyosin and smoothelin and the that the decrease in the
contraction of smooth muscle isolated from colitis mouse colon is attributable to the increase in
thin-filament associated proteins. Whether the changes in the expression of smooth muscle
markers and the decrease of contraction are the cause or the consequence of disturbed GI tract
motility remains to be determined.

The changes smooth muscle contractile proteins, assessed

here in inflammation, appear appropriate to associate to the functional alterations of the smooth
muscle cell, and this was not studied before. A relatively minor role under physiological
condition may a determining factor contributing to dysfunction of smooth muscle in diseases. In
deed, changes in the expression of contractile proteins were demonstrated in various
pathophysiological situations. Future studies of the mechanisms involved in the up-regulation of
these proteins might provide more understanding of the molecular pathways involved in the
expression of contractile protein regulation. Targeting these pathways in the regulation of
colonic muscle contraction would be interesting. Clearly, a comprehensive appraisal of the
enteric muscle contractile proteins and signal transduction pathways, in addition to the
evaluation of enteric neurons and ICC, may contribute to further characterization of mechanisms
underlying gastrointestinal motility disorders.
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